



Form PTO-1449

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.
0283-0192PUS1APPLICATION NO.
10/827,294APPLICANT
KUBO, Akira et al.FILING DATE
April 20, 2004GROUP
Unassigned-1624**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	Kind	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
DR	US 4,532,250	A	1985-07-30	Stout et al.	----	----	
DR	US 3,538,104		1970-11-03	Gruenfeld, N.	----	----	
DR	US 6,329,526	B1	2001-12-11	Adams et al.	----	----	
DR	US 6,677,337	B2	2004-01-13	Laufersweiler et al.	----	----	
DR	US 6,566,357	B1	2003-05-20	Laufersweiler et al.	----	----	
DR	US 6,730,668	B2	2004-05-04	Clark et al.	----	----	
DR	US 2003/0105084	A1	2003-06-05	Clark et al.	----	----	
DR	US 6,579,874	B2	2003-06-17	Revesz et al.	----	----	
	US						
	US						

FOREIGN PATENT DOCUMENTS

	Office	DOCUMENT NUMBER	Kind	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
								YES	NO
DR	JPO	10-291982	A	1998-04-11	JAPAN	----	----	X	
DR	EP	1205478	A1	2002-05-15	EPO	----	----		
DR	EP	1180518	A1	2002-02-20	EPO	----	----		

OTHER DOCUMENTS

(Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.)

DR	Robert W. Carling, et al., "1-(3-Cyanobenzylpiperidin-4-yl)-5-methyl-4-phenyl-1,3-dihydroimidazol-2-one: A Selective High-Affinity Antagonist for the Human Dopamine D ₄ Receptor with Excellent Selectivity over Ion Channels", <i>J. Med. Chem.</i> 1999, 42, 2706-2715.
DR	Winton D. Jones, Jr., et al., "The Synthesis and Biological Activity of Pyridyl-2(3H)-Oxazolones", <i>Proceedings: NOBCCHe '94</i> , volume 21, August 1994., 100-115.
DR	Jeffrey C. Boehm & Jerry L. Adams, "Expert Opinion on Therapeutic Patents, "New inhibitors of p38 kinase", <i>Ashley Publications Ltd.</i> , ISSN 1354-3776 (2000), 25-37.
DR	Stephen E. deLaszlo et al., "Pyrroles and Other Heterocycles as Inhibitors of P38 Kinase", <i>Bioorganic & Medicinal Chemistry Letters</i> 8 (1998) 2689-2694.

EXAMINER

/Deepak Rao/

DATE CONSIDERED

02/27/2007

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.S.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.

0283-0192PUS1

APPLICATION NO.

10/827,294

APPLICANT

KUBO, Akira et al.

FILING DATE

April 20, 2004

GROUP

1625- 1624

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	Kind	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	US						
	US						
	US						
	US						
	US						
	US						
	US						
	US						
	US						
	US						

FOREIGN PATENT DOCUMENTS

	Office	DOCUMENT NUMBER	Kind	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
								YES	NO
DR	WO	WO 02/076974	A2	2002-10-03	WIPO	---	---		

OTHER DOCUMENTS

(Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.)

EXAMINER

/Deepak Rao/

DATE CONSIDERED

02/27/2007

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.S.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.